<?xml version="1.0" encoding="UTF-8"?>
<p id="p0310">As an additional feature, the tool also presents some of the work completed by WG2, which was undertaken to better understand the feasibility and challenges of developing vaccines for the major UKVN prioritised pathogens. The UKVN members agreed that to develop a new vaccine might not always be the most appropriate response in an outbreak setting, particularly if a candidate vaccine is early stage and presents significant R&amp;D or manufacturing challenges. Thus, it may be more appropriate to deploy other healthcare interventions to manage the disease, such a therapeutic antibodies or containment procedures.</p>
